Centro de Investigación de Medicina Aplicada (CIMA)
Centro / Instituto vinculado a la Universidad de Navarra
Weill Cornell Medical College in Qatar
Doha, QatarPublicaciones en colaboración con investigadores/as de Weill Cornell Medical College in Qatar (9)
2024
-
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3
-
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4
2021
-
Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: The COMBAT/ KEYNOTE-202 trial
Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5020-5027
2020
-
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1
2019
-
Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis
Clinical Cancer Research, Vol. 25, Núm. 15, pp. 4663-4673
-
Use of machine-learning algorithms in intensified preoperative therapy of pancreatic cancer to predict individual risk of relapse
Cancers, Vol. 11, Núm. 5
2016
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2014
-
Classification of current anticancer immunotherapies
Oncotarget, Vol. 5, Núm. 24, pp. 12472-12508
2012
-
Identification of LMO2 transcriptome and interactome in diffuse large B-cell,lymphoma
Blood, Vol. 119, Núm. 23, pp. 5478-5491